Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen®) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis
✍ Scribed by Susanne Freeman; Anne Howard; Peter Foley; Robert Rosen; Glenda Wood; Jo-Ann See; Susan Gray
- Book ID
- 104469135
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 133 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0004-8380
No coin nor oath required. For personal study only.
✦ Synopsis
SUMMARY
The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild‐ to mid‐potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. Eighty‐one adult patients were randomized to receive desonide 0.05% lotion or its vehicle, applied twice daily for 3 weeks under double‐blind conditions. In the active treatment group, 88% of patients had their skin condition cleared or almost cleared and only two patients experienced cutaneous adverse events (rash and pruritus). The acceptability of the lotion was high; 95% of patients stated they would use this topical corticosteroid again. These data support the short‐term use of desonide 0.05% lotion as a suitable agent for the short‐term treatment of facial dermatitis.